Novadiol, Inc., is a Kansas City-based biopharmaceutical company developing first-in-class treatments for secondary hyperparathyroidism (SHPT) and hypovitaminosis D. Novadiol’s Investigational New Drug (IND), known as NVCKD-001, will treat secondary hyperparathyroidism (SHPT) in stage 3 and stage 4 chronic kidney disease (CKD) patients.  Novadiol has the worldwide rights to the patented, once-a-week administration of this molecule.

Over 20 million patients suffer from CKD in the U.S.  More than 4 million of these patients have stages 3 or 4 CKD and suffer from SHPT.   Novadiol will begin a Phase 1 clinical trial of NVCKD-001 in March, 2016.  Novadiol anticipates being on the market in 2019 in the U.S., and possibly sooner in other countries.

Novadiol Inc. (www.novadiol.com) was created in 2012 by G.P. Georges, specifically to develop NVCKD-001.  Georges is an entrepreneur who started Nephro-Tech Inc., a renal vitamin company, in 1992, of which he holds the CEO position today.  He also created FocalHealth LLC (www.focalhealth.com), a dietary supplement company, in 2013, to develop and market a new calcium dietary supplement (FormiCal) based on a new calcium source not currently being marketed. (Calcium Formate - it absorbs 3 times faster than the leading calcium products on the market today.)

Novadiol Inc. is continuing to raise investment capital in the NVCKD-001 project.  Interested investors can contact the business development group at Novadiol at bd@novadiol.com.